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Immunodeficiency in non-tuberculous mycobacterial 
disease 
K. S. FROEBEL**, F. G. E. B~LLERT+, J. JELLEMA”, A. G. BIRD” AND A. P. GREENING+ 
“HIV Immunology Unit, Univevsify Department of Medicine and ‘Respiratory Unit, 
Wesfevn General Hospital, Edinburgh, U.K. 
T-cell immunity was investigated in eight patients with non-tuberculous mycobacterial disease, to see 
whether impaired immune function might be the explanation for their infection. Cellular immune 
_“unctio~ was evahuated irz vitro by measuring the proliferation cf peripheral blocd mononuclear cells in. 
response to both non-specific mitogens (phytohaemagglutinin and pokeweed mitogen) and specific recall 
antigens (streptokinase-streptodornase and purified protein derivative from Mycobacteuium tubevculo- 
six), and in vivo, by measuring the skin test response to a panel of recall antigens. Functionally relevant 
T-lymphocyte sub-populations (CD4, CD8, activated CD3 and y/6 T-cells) were enumerated by 
two-colour flow cytometry. The results were compared with those for a group of patients with 
pulmonary tuberculosis, with groups of controls matched for age and smoking habit, and with a patient 
group receiving steroid treatment. The patients with non-tuberculous mycobacterial disease had poor or 
absent skin test responses; in vitro, their response to recall antigens was depressed, although their 
response to mitogens was normal. The patients had significantly raised levels of CD8 lymphocytes and 
activated T-cells, but lacked any circulating y/S T-cells. There were also differences between the various 
control groups. In conclusion, this study demonstrates a deficiency in the cellular immune system of these 
patients, which is most readily detectable by skin testing, or by measuring lymphocyte proliferative 
responses to recall antigens. However, the study also shows changes in cellular immune responses in 
controls matched for age and smoking and in patients on steroid treatment, and underscores the need for 
matched controls. Further work needs to be done to ascertain whether the cellular immune deficiency is 
a cause of, or is caused by, the mycobacterial infections, and also to investigate the pathological 
significance of the alterations in T-cell sub-populations. 
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Introduction 
The mycobacteria reference laboratory in 
Edinburgh has reported increasing numbers of 
mycobacterial isolates over recent years, in par- 
ticular with non-tuberculous organisms such as 
M. avium complex (MAC) and iU. nzalmoense 
(1). The cause of the rise is not known. The 
global increase in tuberculosis (TB) over the 
last few years has in part been attributed 
to immunosuppression secondary to human 
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immunodeficiency virus (HIV) infection (2). This 
observation is not confirmed in Edinburgh 
where, despite a high incidence of HIV infection, 
TB notifications have fallen, and the number of 
TB cases in HIV-positive patients is lower than 
would be expected (3). 
The cellular immune system plays an import- 
ant role -in the immune response to myco- 
bacterial infection [reviewed by Ellner and 
Wallis (4)], and re-activation or re-infection can 
occur in patients in whom T-cell immunity is 
impaired. Immunocompromised patients and 
those with lung destruction secondary to pre- 
vious tuberculosis or co-existing pneumoconio- 
sis and pulmonary fibrosis are also prone to 
non-tuberculous mycobacterial infections. The 
authors’ clinical impression that apparently 
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immunocompetent patients, presenting to the 
Respiratory Unit at the Western General Hospi- 
tal with symptoms and chest radiograph findings 
suggestive of pulmonary tuberculosis, were diag- 
nosed to have non-tuberculous mycobacterial 
disease (5), led to a study of cellular immunity in 
this group. 
T-cell-mediated immunity can be evaluated 
in vitro, by measuring the proliferative responses 
of lymphocytes to specific and non-specific 
stimulants, and in vivo by skin testing. Phyto- 
haemagglutinin (PHA) and pokeweed (PWM) 
are non-specific mitogens which stimulate T- or 
T- and B-lymphocytes, respectively. Strepto- 
kinase streptodornase (SKSD) is a common 
environmental antigen, derived from Eschericha 
coli, to which most of the population is sensi- 
tized. Purified protein derivative of M. tubercu- 
losis (PPD) is an antigen to which most adults 
will have been sensitized, either by immunization 
with BCG or by natural infection. Therefore, a 
high level of response to these two antigens 
would be expected in an immunocompetent 
population. Cutaneous challenge with environ- 
mental and pathogenic organisms measures the 
delayed type hypersensitivity arm of the cellular 
immune response repertoire. Immune status may 
also be assessed by lymphocyte subset analysis. 
A reduction in circulating CD4 (helper) T-cells 
is indicative of immune deficiency; raised CD8 
(suppressor/cytotoxic) T-cells or activated 
(HLA-DR positive) T-cells are indicative of 
immune activation. T-cells with the y/6 T-cell 
receptor chains have been shown, in mice, to be 
increased in the lymph nodes draining sites which 
have been injected with M. tuberculosis, and in 
the lungs of infected animals (6), and they are 
thought to be important in the first line of 
defence to mycobacterial infections (7,8). 
Patients and Methods 
SUBJECTS 
Seventeen patients who attended the Respir- 
atory Unit at the Western General Hospital, 
Edinburgh, with non-tuberculous mycobacterial 
disease (n = 8) or pulmonary TB (n = 9) during the 
period April 1990 to March 1993 gave informed 
consent to have blood taken for HIV testing, 
lymphocyte subset analysis and functional 
studies. The study was approved by the Lothian 
Health Area Ethics Committee. 
All patients with pulmonary isolates of non- 
tuberculous mycobacteria, except one in whom 
the diagnosis was made on a lobectomy speci- 
men, had at least two positive cultures at differ- 
ent times (mean: eight positive cultures, range 
2-29) and new chest radiographic changes 
suggestive of mycobacterial disease, consistent 
with the diagnostic criteria of non-tuberculous 
pulmonary mycobacteriosis, as listed by the 
American Thoracic Society (9). Five patients 
had underlying lung disease. Three of these had 
asthma/chronic obstructive pulmonary disease 
(COPD), of whom one also had relapsed non- 
tuberculous pulmonary disease. A further 
patient had pulmonary fibrosis, for which she 
has been on maintenance oral prednisolone 
(5 mg day - ‘), and relapsed non-tuberculous 
pulmonary disease, and the fifth patient had 
previous pulmonary TB. None of the patients 
had any personal or family history of immuno- 
suppression. All patients received treatment with 
varying combinations of anti-mycobacterial 
drugs containing at least rifampicin and etham- 
butol for a median of 20 months. Treatment is 
ongoing after 45 months in one patient with 
persistently positive cultures for MAC. At the 
time blood was taken for laboratory tests, five 
patients were receiving, and three patients had 
completed, treatment (duration 20, 20 and 22 
months). All were HIV negative. In the group 
of patients with pulmonary TB, one had 
re-activation of previous disease and one had 
co-existing asthma. The group divided into seven 
patients on treatment, and two patients post- 
treatment. The demographic and clinical details 
of the patients are summarized in Tables 1 and 2. 
Three groups of controls were tested: (1) nor- 
mal controls (NC, y1= lo), who were plasma 
donors attending the South-east of Scotland 
Blood Transfusion Service; (2) patient controls 
(PC, y1=9), matched for age, smoking history 
and pulmonary disease other than mycobacterial 
disease; and (3) patient controls on maintenance 
oral prednisolone (SC, y1=4, 5-10 mg day ~ ‘) to 
control for the effect of steroids (Table 2). The 
normal controls were all HIV negative; the 
patient controls did not have their HIV status 
checked, but none of these patients had any risk 
factors for HIV infection. 
TABLE 1. Details of patients and controls 
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No. 
Sex Mean age 
(M/F) (year) (range) 
Smoking history 
nonlex-/smoker 
BCG 
YlN/NK 
Oral steroids 
YIN 
Non-tuberculous mycobacteria: 
M. malmoense 6 214 
M avium complex 1 O/I 65 (54-73) O/6/2 21412 II7 
M. xenopi 1 l/O 
M. tuberculosis 9 613 57 (21-81) 21413 3/5/I o/9 
Patient controls 9 514 59 (39-70) l/5/3 NK o/9 
Steroid controls 4 4/o 70 (64-78) o/4/0 NK 4/o 
Normal controls 10 713 37 (21-51) NK NK o/10 
Total 40 25115 
Y, yes; N, no; NK, not kno,wn. 
TABLE 2. Skin test results 
Patient Sex (M/F) BCG 
Compound 
score* 
Tuberculin 
300 000 IU ml - I+ 
M. malmoense 
1 
21 
3 
4 
5 
6 
A4 avium complex F 
M. xenopi M 
F 
F 
F 
F 
M 
M 
NK 6/l Neg 
NK 4/l Neg 
Y 412 Neg 
N 1714 3.5 
NK o/o Neg 
Y 1 l/3 4 
N 24l3 
N 5/l 
10.5 
4.5 
Results of the Multitest skin test kit. *The first figure is the total induration from eight 
challenges, measured as the diameter in mm; the second figure is the number (out of eight) 
positive responses. ‘The response to tuberculin measured as the average mm induration. 
$On prednisolone. Y, yes; N, no; NK, not known. 
METHODS 
Lymphocyte proliferation 
Peripheral blood mononuclear cells (PBMC) 
were separated from 20 ml of heparinized blood 
using ficoll-hypaque and stored in liquid nitro- 
gen until use. Before use, the PBMC were 
thawed slowly, washed and checked for viability 
using trypan blue exclusion. Only samples with a 
high viability of PBMC (>80%) after thawing 
were used. PBMC were re-suspended at a con- 
centration of 0.3 x 1 O6 cells ml - * in RPM1 1640 
medium (GIBCO, Paisley) containing glutamine, 
antibiotics and 10% human AB serum. Cultures 
of PBMC were set up in triplicate, in round 
bottomed microtitre plates, with concentrations 
of each antigen and mitogen chosen in prelimi- 
nary standardization experiments to give opti- 
mal stimulation. PPD and SKSD were dialysed 
before use, and reconstituted to the original 
volume. PHA (PHA-p, Wellcome, Beckenham) 
was used at 5yg ml-‘, PWM (Sigma, Poole) at 
0.25pg ml-l, PPD at 500 units ml - 1 and 
SKSD at 25pg ml-‘. To check for day-to-day 
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FIG 1. Proliferative responses of lymphocytes to (a) mitogens phytohaemagglutinin (PHA) and pokeweed 
(PWM, and (b) antigens streptokinase streptodornase (SKSD) and purified protein derivative of JJ~~obac- 
tevium tuberculosis (PPD). Results are expressed as the mean counts per minute +SEM for patients with non- 
tuberculous mycobacterial disease (solid bars), patients with pulmonary tuberculosis (hatched bars), patient 
controls on steroids (cross-hatched bars), patient controls (stippled bars) and normal controls (open bars). 
*P<O.O5, fP<O.Ol compared with controls. 
variation, an aliquot of PBMC from the same 
donor was tested each day together with the 
patient and control samples. The cultures were 
incubated at 37°C and 5% CO, for 120 h. Pro- 
liferation was measured as counts per minute 
(cpm) using a betaplate counter (Wallac) by 
incorporation into DNA of 3H-thymidine, 
added for the final 4 h of culture. 
Lymphocyte subset analysis 
Lymphocyte subset analysis was carried out 
using fresh EDTA blood, and pairs of anti- 
bodies, directly conjugated with either fluoro- 
icothiocyanate (FITC) or phycoerythrin (PE), 
as described previously (10). Anti-CD3(FITC)/ 
anti-HLA-DR(PE) and anti-CD4(FITC)/anti- 
CD8(PE) were obtained from Becton-Dickenson 
(Oxford); anti-$ (PE) was obtained from T Cell 
Sciences (Cambridge, MA, U.S.A.). The samples 
were read on a ‘FACscan’ flow cytometer and 
analysed using ‘Simulset’ software (Becton- 
Dickenson). 
Skin testing 
Skin testing was performed on the eight patients 
with non-tuberculous mycobacteriosis, using the 
‘Multitest-CMI’ applicator (Institut Merieux, 
Lyon, France) according to the manufacturer’s 
instructions. The multi-head applicator delivers 
challenge doses of the following antigens intra- 
dermally: tetanus, diphtheria, streptococcus, 
tuberculin, candida, trichophyton, proteus and a 
glycerin control, and the response is read as the 
mean induration (mm) after 48 h. 
Statistical analysis 
Data were analysed using ‘Minitab’ statistical 
software (11). The proliferation data were first 
transformed to logarithms to give a normal 
distribution. The mean results of both the pro- 
liferation assays and lymphocyte phenotyping 
were first compared using one-way analysis of 
variance. Patient results that appeared to be 
different were then compared to both the normal 
and patient control groups using Student’s t-test. 
Results 
LYMPHOCYTE PROLIFERATION 
The results expressed as the mean cpm f SEM are 
shown in Fig. 1. The response to PHA was 
slightly but not significantly reduced in the 
patients with non-tuberculous mycobacterial 
disease. There were no significant differences in 
the responses to PWM. The responses to SKSD 
of both non-tuberculous mycobacterial and pul- 
monary TB patient groups were significantly 
lower than both the NC and PC groups (PcO.05) 
and similar to the SC group. The mean response 
to PPD of the PC group was higher than that of 
the NC group (P<O.Ol). 
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FIG. 2. Lymphocyte subsets in patients and controls. Results are expressed as (a) the mean number (f SEM) 
of CD4 and CD8 lymphocytes per ,I.J of blood, and (b) the mean percentage (+ SEM) of T-cells which are 
HLA-DR or y/6 positive. Groups are as for Fig. 1. *P<O.O5, yWO.01 compared with controls. 
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SKIN TESTING 
The results are shown in Table 2. Seven 
(of eight) patients had either a negative or a 
negligible response to tuberculin. Five had a low 
combined score to all the antigens; in one patient 
(No. 5), it was completely negative. 
LYMPHOCYTE SUBSET ANALYSIS 
The results are expressed as the mean absolute 
number of cells per ~1 of blood for CD4 and 
CD8 cells, and as percentages of T-cells for 
HLA-DR positive and y/d positive cells (Fig. 2). 
The mean numbers of circulating CD4 cells were 
not different between the groups. There were 
differences, however, in both the number of 
circulating CD8 cells and in the percentage 
of HLA-DR positive T-cells, with the patient 
groups with non-tuberculous mycobacterial dis- 
ease and pulmonary TB having raised levels of 
both, compared with normal controls (P<O.Ol). 
The non-tuberculous mycobacterial group also 
had a lower mean percentage of y/6 T-cells 
compared with all the other groups (PcO.05). 
The PC group had raised CD8 cells but normal 
levels of HLA-DR positive T-cells. In all the 
groups, the individual patients with the highest 
level of HLA-DR+ T-cells also had the highest 
percentage of CD8 cells (data not shown). 
Discussion 
This study investigated whether depressed T- 
cell immunity might explain the observation 
of increased cases of non-tuberculous pulmon- 
ary mycobacteriosis in apparently immuno- 
competent patients. Lymphocyte proliferative 
responses to PHA, PWM and PPD were normal 
in these patients. The proliferative response to 
the environmental antigen SKSD was signifi- 
cantl) reduced in patients with non-tuberculous 
disease or with pulmonary TB infections. The 
age-matched group of patient controls who also 
had lung disease had a significantly higher 
response to PPD than the healthy volunteers. 
Skin test responses in the eight patients with 
non-tuberculous mycobacterial disease, to a 
range of antigens were reduced, with the 
response to tuberculin being particularly low. 
The patients with non-tuberculous mycobac- 
terial disease had significantly higher levels of 
circulating CD8 cells and activated (HLA-DR + ) 
cells, and lower levels of y/6 T-cells. 
Ellner and Wallis (4) also found normal 
PHA responses, but depressed proliferation in 
response to SKSD and PPD in a group of 
patients with newly &Lgnosed active pulmonary 
TB, associated with skin anergy to tuberculin. 
They attributed the suppression of proliferative 
responses, in a subset of patients, to a soluble 
inhibitor released by circulating monocytes. 
Azarbe et al. (12) showed a reduced proliferative 
response to PPD, but normal responses to SKSD 
and to Candida albicans in untreated patients 
with pulmonary TB. Their patient popu- 
lation was younger than that in the present study 
132.4 years VS. 57 years (pulmonary TB group), 
and 65 years (non-tuberculous group)], and all 
patients and controls had previous BCG vacci- 
nation (three of nine patients in the present 
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study). In the present study, both patient groups, 
those with non-tuberculous mycobacterial dis- 
ease and those with pulmonary TB, showed a 
reduced response to SKSD compared to both 
the NC and the PC groups, suggesting either a 
loss of these memory cells, or a defect at the 
early, proliferative stage of the lymphocyte 
response. 
The responses to PPD are complex. The more 
vigorous response of the PC group compared 
with the NC group is difficult to explain. The 
differences between the two groups are age (22 
year difference in mean age) and smoking habit. 
Although lymphocyte proliferation generally 
tends to decrease with age, the risk of previous 
non-tuberculous mycobacterial infection or pul- 
monary TB increases with age, which may 
explain the increased response to this antigen. 
To the authors’ knowledge, perturbation of 
peripheral lymphocyte function by smoking has 
not been observed. The separation of in vitro and 
in vivo responses to tuberculin have been 
described previously (13). It suggests that there is 
a cellular immune defect, which is downstream 
of the proliferative response, possibly at the level 
of release of inflammatory cytokines, or resulting 
from a difference in the proportions of T-helper 
cell subsets (14). 
An increase in circulating CD8 cells has been 
reported previously in patients with non- 
tuberculous mycobacterial disease by Tomoda 
et al. (15). However, to the present authors’ 
knowledge, increased HLA-DR + T-cells have 
not been described previously in mycobacterial 
infections. The importance of CD8 lymphocytes 
as cytotoxic and suppressor cells in the immune 
response to mycobacterial and viral infections is 
being recognized increasingly, and these cells 
express the HLA-DR antigen on activation 
(16,17). In patients with mycobacterial infec- 
tions, CD4 + cytotoxic cells have been described, 
which can lyse autologous macrophages present- 
ing mycobacterial antigens in a reaction which is 
inhibited by antibody to HLA-DR (18). Thus 
the HLA-DR+ T-cells observed here may be 
activated or cytotoxic CD4 or CD8 cells. The 
result which distinguishes the two patient groups 
is the virtual absence of y/6 T-cells in the periph- 
eral blood of patients with non-tuberculous 
mycobacterial disease. y/6 cells are known to 
respond in high frequency to mycobacteria (8). 
They are localized in the gut and epithelial 
tissues, where they are thought to be the first line 
of defence against mycobacterial infections (7), 
and they home to the lymph node draining the 
site of infection (6). Lorgat et al. (19) and Rossi 
et al. (20) have also suggested that the cellular 
immune response is localized in the sites of 
disease activity, based on their observation that 
proliferation and cytotoxicity in PPD-stimulated 
lymphocytes from tuberculous pleural effusions 
is increased compared to those in autologous or 
control blood. The virtual absence of y/6 cells in 
the circulation of patients with non-tuberculous 
mycobacterial disease could therefore be a con- 
sequence of the cells homing to the lymph nodes 
or to the sites of disease activity. Alternatively, 
their susceptibility to mycobacterial infection 
may be a consequence of a lack of y/6 cells. 
In conclusion, this study has shown that 
patients with non-tuberculous mycobacterial 
disease have evidence of impaired cellular 
immunity. The finding of increased CD8+ and 
activated (HLA-DR+) T-cells with virtual 
absence of y/S cells in peripheral blood, and 
impaired skin test responses, merits further 
investigations. It remains to be established, how- 
ever, whether mycobacterial infection is caused 
by, or causes, the impaired cellular immunity. 
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